Authors
Latest:
Escaping the Void: All Things Biosimilars With Craig & GTo close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.
Latest:
The Pandemic's Multilevel Effect on Patient AccessCoronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.
Latest:
AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.
Latest:
Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and BeyondHurdles to a vibrant biosimilar market are not as insurmountable as they appear.
Latest:
Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.
Latest:
New Rule: Transition to BLA Pathway Is CompleteAs of today, the FDA has completed a 10-year process to bring a wider set of biologics under the biologics license pathway for approval.
Latest:
Follow the Science: Bridging the Biosimilar Gap With Dr Hillel CohenExplore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization in this engaging podcast episode.
Latest:
Drug Couponing: Better or Worse for Biosimilars?Payers will have to carefully mull limited options.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
Latest:
Another European Study Finds SB4 Tolerated by Most PatientsThe study follows others that have found that SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.
Latest:
Lupin Partners With Mylan on Etanercept BiosimilarLupin recently announced that it has entered into a partnership agreement with Mylan to commercialize its proposed etanercept (Enbrel) biosimilar.
Latest:
COVID-19's Multifaceted Effect on BiosimilarsThe coronavirus disease 2019 (COVID-19) effect on the biosimilar industry will be deep and lasting, causing not just approval and launch delays but profound structural changes in how business is done.
